A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment

The goal of the clinical trial is to collect safety data and information on how the body processes BVd in people with multiple myeloma (MM) who have moderate liver problems, compared with similar participants who have normal liver function. It also compares how liver problems affect the body's handling of belantamab mafodotin and uses the results to help set safe and appropriate dosing guidance for MM participants with moderate liver problems.

NCT Number	NCT07609706
Lead Sponsor	GlaxoSmithKline
Conditions	Multiple Myeloma
Enrollment	20 participants
Start Date	2026-10-23
Primary Completion	2031-08-22 (estimated)
Study Completion	2031-08-22 (estimated)
Updated on ClinicalTrials.gov	2026-05-27